Probiotics:: effects on immunity
Probiotics:: effects on immunity
复制标题
DOI：
10.1093/ajcn/73.2.444s
复制
发表时间：
2001-02-01
影响因子：
7.1
通讯作者：
Salminen, S
中科院分区：
文献类型：
--
作者：
Isolauri, E;Sütas, Y;Salminen, S
胃肠道起着抵御微生物和食物抗原的屏障作用。肠道免疫生理调节的产生依赖于本土微生物区系的建立。这导致了基于消费作为益生菌的有益活微生物的培养而引入的从不治疗的干预措施。益生菌治疗的可能机制之一是促进非免疫性肠道防御屏障，包括使增加的肠道通透性正常化和改变肠道微生态。益生菌治疗的另一个可能机制是改善肠道的免疫屏障，特别是通过肠道免疫球蛋白A反应和减轻肠道炎症反应，从而产生稳定肠道的作用。许多益生菌的作用是通过免疫调节，特别是通过平衡控制促炎和抗炎细胞因子来实现的。这些数据表明，益生菌可以作为创新工具来缓解肠道炎症，正常化肠道粘膜功能障碍，并下调过敏反应。最近的数据显示，候选益生菌的免疫调节作用存在差异。此外，在健康受试者和炎症性疾病患者中也检测到了明显的调节作用。这些结果表明，当开发扩大目标人群的临床应用时，应该表征益生菌的特定免疫调节特性。
The gastrointestinal tract functions as a barrier against antigens from microorganisms and food. The generation of immunophysiologic regulation in the gut depends on the establishment of indigenous microflora. This has led to the introduction of never therapeutic interventions based on the consumption of cultures of beneficial live microorganisms that act as probiotics. Among the possible mechanisms of probiotic therapy is promotion of a nonimmunologic gut defense barrier, which includes the normalization of increased intestinal permeability and altered gut microecology. Another possible mechanism of probiotic therapy is improvement of the intestine's immunologic barrier, particularly through intestinal immunoglobulin A responses and alleviation of intestinal inflammatory responses, which produce a gut-stabilizing effect. Many probiotic effects are mediated through immune regulation, particularly through balance control of proinflammatory and antiinflammatory cytokines. These data show that probiotics can be used as innovative tools to alleviate intestinal inflammation, normalize gut mucosal dysfunction, and down-regulate hypersensitivity reactions. More recent data show that differences exist in the immunomodulatory effects of candidate probiotic bacteria. Moreover, distinct regulatory effects have been detected in healthy subjects and in patients with inflammatory diseases. These results suggest that specific immunomodulatory properties of probiotic bacteria should be characterized when developing clinical applications for extended target populations.